Elapegademase-lvlr ( DrugBank: Elapegademase, Elapegademase-lvlr )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 65 | Primary immunodeficiency | 1 |
65. Primary immunodeficiency
Clinical trials : 482 / Drugs : 653 - (DrugBank : 119) / Drug target genes : 92 - Drug target pathways : 212
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03878069 (ClinicalTrials.gov) | June 25, 2019 | 12/3/2019 | Registry Study of Revcovi Treatment in Patients With ADA-SCID | Single Arm, Open-Label, Multicenter, Registry Study of Revcovi (Elapegademase-lvlr) Treatment in ADA-SCID Patients Requiring Enzyme Replacement Therapy | Adenosine Deaminase Deficiency;Severe Combined Immunodeficiency | Biological: elapegademase-lvlr | Chiesi Farmaceutici S.p.A. | NULL | Recruiting | N/A | 65 Years | All | 20 | United States |